MX2024008162A - Formulaciones parenterales estimulantes respiratorias. - Google Patents

Formulaciones parenterales estimulantes respiratorias.

Info

Publication number
MX2024008162A
MX2024008162A MX2024008162A MX2024008162A MX2024008162A MX 2024008162 A MX2024008162 A MX 2024008162A MX 2024008162 A MX2024008162 A MX 2024008162A MX 2024008162 A MX2024008162 A MX 2024008162A MX 2024008162 A MX2024008162 A MX 2024008162A
Authority
MX
Mexico
Prior art keywords
parenteral formulations
respiratory stimulant
compound
disclosed
stimulant
Prior art date
Application number
MX2024008162A
Other languages
English (en)
Spanish (es)
Inventor
Isaac Agyemang
Joseph V Pergolizzi
Frank Diana
Jiayi Chen
Devon E Dodd
Original Assignee
Enalare Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enalare Therapeutics Inc filed Critical Enalare Therapeutics Inc
Publication of MX2024008162A publication Critical patent/MX2024008162A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MX2024008162A 2021-12-27 2022-12-23 Formulaciones parenterales estimulantes respiratorias. MX2024008162A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163293985P 2021-12-27 2021-12-27
US202263313472P 2022-02-24 2022-02-24
PCT/US2022/053935 WO2023129502A1 (en) 2021-12-27 2022-12-23 Respiratory stimulant parenteral formulations

Publications (1)

Publication Number Publication Date
MX2024008162A true MX2024008162A (es) 2024-09-17

Family

ID=86992921

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024008162A MX2024008162A (es) 2021-12-27 2022-12-23 Formulaciones parenterales estimulantes respiratorias.

Country Status (9)

Country Link
US (1) US20230210857A1 (https=)
EP (1) EP4456900A4 (https=)
JP (1) JP2025501169A (https=)
KR (1) KR20240150426A (https=)
AU (1) AU2022426492A1 (https=)
CA (1) CA3242509A1 (https=)
MX (1) MX2024008162A (https=)
TW (1) TW202333732A (https=)
WO (1) WO2023129502A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230414624A1 (en) * 2022-06-24 2023-12-28 Enalare Therapeutics Inc. Methods of treating neurological ventilatory insufficiency

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199901968T2 (xx) * 1996-12-24 1999-12-21 Biogen, Inc. Sabit s�v� interferon form�lleri.
US20120295911A1 (en) * 2010-11-29 2012-11-22 Galleon Pharmaceuticals, Inc. Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases
AU2011336764B2 (en) * 2010-11-29 2017-02-23 Galleon Pharmaceuticals, Inc. Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases
DK2701684T3 (en) * 2011-04-28 2017-09-18 Platform Brightworks Two Ltd Improved parenteral formulations of lipophilic pharmaceuticals and methods for their preparation and use
SG11201503505QA (en) * 2012-11-15 2015-06-29 Galleon Pharmaceuticals Inc Novel orally bioavailable breathing control modulating compounds, and methods of using same
GB201502412D0 (en) * 2015-02-13 2015-04-01 Canbex Therapeutics Ltd Therapeutic use

Also Published As

Publication number Publication date
AU2022426492A1 (en) 2024-07-18
KR20240150426A (ko) 2024-10-15
CA3242509A1 (en) 2023-07-06
EP4456900A1 (en) 2024-11-06
WO2023129502A1 (en) 2023-07-06
TW202333732A (zh) 2023-09-01
JP2025501169A (ja) 2025-01-17
US20230210857A1 (en) 2023-07-06
EP4456900A4 (en) 2025-12-24

Similar Documents

Publication Publication Date Title
MX2023014620A (es) Nuevos profarmacos y conjugados de dimetiltriptamina.
WO2023192602A3 (en) Respiratory stimulant nasal formulations
NZ600231A (en) Pharmaceutical compositions comprising sigma receptor ligands
SG10201407538WA (en) Intravenous formulations of neurokinin-1 antagonists
MX2021003739A (es) Derivados de quinolino-pirrolidin-2-ona como inhibidores del gen mutado de ataxia telangiectasia (atm) y el uso de los mismos en el tratamiento de tumores sólidos.
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
NZ592970A (en) Oral dosage forms of bendamustine
AR040434A1 (es) Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
MX2024014628A (es) Compuesto para inhibir o degradar bcl6 y uso de este en farmacia
NO20051389L (no) Stabilisert farmasoytisk blanding inneholdende basiske hjelpemidler
SG165162A1 (en) Modified release pharmaceutical formulation
WO2023129956A3 (en) Dimethyltryptamine analogues as nitric oxide delivery drugs
MX2024009177A (es) Compuestos y metodos de uso
MX2023011464A (es) Inhibidores de la cinasa relacionada con el gen nunca en mitosis a 7 (nek7).
MX2024008162A (es) Formulaciones parenterales estimulantes respiratorias.
PH12022550531A1 (en) Irak inhibitor and preparation method therefor and use thereof
MX2023009052A (es) Compuesto de bifenilo como inmunomodulador, método de preparación para el mismo y uso del mismo.
MX2023013225A (es) Inhibidores de la cinasa 4 similar a polo.
GEAP202516737A (en) Compounds for treating cancer
TW200607508A (en) Powder formulations for inhalation, comprising enantiomerically pure beta agonists
SE0201658D0 (sv) Immediate release pharmaceutical formulation
CO2022008616A2 (es) Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma
WO2010080339A4 (en) Phenylephrine formulations with improved stability
WO2021102161A8 (en) Methods for treating inflammatory bowel disease
WO2011080570A3 (en) Extended release pharmaceutical composition comprising linezolid and process for preparing the same